Zacharia BE, Gulati AP, Bruce JN, Carminucci AS, Wardlaw SL, Siegelin M, Remotti H, Lignelli A, Fine RL. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery. 2014 Apr;74(4):E447-55; discussion E455. doi: 10.1227/NEU.0000000000000251.
Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, Mowatt KB, Dinnen RD, Mao Y, Stevens PD, Schrope B, Allendorf J, Lee JA, Sherman WH, Chabot JA. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother. Pharmacol. 2013 Mar;71(3):663-70. doi: 10.1007/s00280-012-2055-z. Epub 2013 Jan 31.
Gulati AP, Krantz B, Moss RA, Moyal WN, Tsushima DA, Mowatt KB, Schreibman S, Fine RL. Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature. Oncology. 2013;84(3):127-34. doi: 10.1159/000342961. Epub 2012 Dec 8.
Gulati AP, Saif MW. Is there a role for liver transplantation in metastatic pancreatic neuroendocrine tumors (PNET)? JOP. 2012 May 10;13(3):320-1.
Gulati AP, Saif MW. Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST). Anticancer Res. 2012 Apr;32(4):1375-7.
Gulati AP, Domchek SM. The clinical management of BRCA1 and BRCA2 mutation carriers. Curr. Oncol. Rep. 2008 Jan;10(1):47-53.
Gulati AP, Yang YM, Harter D, Mukhopadhyay A, Aggarwal BB, Benzil DL, Whysner J, Albino AP, Murali R, Jhanwar-Uniyal M.
Mol Carcinog. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1.
2006 Jan;45(1):26-37. Erratum in: Mol Carcinog. 2006. Jul;45(7):549.
Donate
Search